期刊文献+

可溶性CD40配体对K562细胞增殖及生存素mRNA和IL-8表达的影响 被引量:1

Effect of soluble CD40 ligand on proliferation of K562 cells and expression level of survivin mRNA
下载PDF
导出
摘要 目的探究可溶性CD40配体(s CD40L)对人白血病K562细胞增殖、生存素(survivin)m RNA表达和白介素8(IL-8)表达水平的影响。方法采用噻唑蓝(MTT)法检测s CD40L对K562细胞增殖的影响,通过RT-PCR检测survivin m RNA表达水平,采用酶联免疫吸附试验(ELISA)测定IL-8表达情况。结果不同浓度的s CD40L(0.5、1.0、1.5、2.0、2.5μg/m L)对K562细胞增殖均有抑制作用,且可降低survivin m RNA及IL-8的表达水平;s CD40L细胞组细胞增殖抑制率高于K562细胞组,survivin m RNA及IL-8表达水平均低于K562细胞组,差异均有统计学意义(P<0.05),且呈剂量-时间依赖性。结论 s CD40L在体外能够明显抑制K562细胞增殖,具有剂量-时间依赖性,s CD40L抑制K562细胞增殖可能与survivin m RNA及IL-8表达水平下调相关。 Objective To investigate the effect of soluble CD40 ligand(s CD40L) on the proliferation of human leukemia K562 cells and expression levels of surviving m RNA and IL-8. Methods The MTT assay was used to examine the effect of different concentrations of s CD40 L on the cellular proliferation,RT-PCR was used to determine the expression level of survivin m RNA;ELISA was used to detect the IL-8 expression. Results Different concentrations of s CD40L(0.5,1.0,1.5,2.0,2.5 μg/m L) all had the inhibiting effect on K562 cell proliferation,moreover could decrease the expression levels of survivin and IL-8;the cellular proliferation inhibiting rate of the s CD40 L cell group was higher than that of the K562 cell group,while the expression levels of surviving m RNA and IL-8 were lower than those in the K562 cell group,the difference was statistically significant(P〈0.05),moreover which showed the dose and time dependent manner. Conclusion s CD40 L can significantly inhibit the proliferation of K562 cells in vitro with the dose and time dependent manner,s CD40 L inhibiting the K562 cell proliferation is correlated with the down-regulation of surviving m RNA and IL-8 expression.
出处 《现代医药卫生》 2016年第4期481-483,486,共4页 Journal of Modern Medicine & Health
基金 贵州省社会发展攻关项目(黔科合SY字[2014]3025号)
关键词 K562细胞 细胞增殖 SURVIVIN基因 白细胞介素8 可溶性CD40配体 K562 cells Cell proliferation Survivin gene Interleukin-8 Soluble CD40 ligand
  • 相关文献

参考文献17

  • 1Asiem B ,Kiran R ,Shweta D ,et al. Current perspectives on the therapeutic aspects of chronic myelogenous leukemia[J]. Expert Opin Ther Patents, 2014,24(10) : 1117-1127.
  • 2Aparna Khandelwal, Mallika Kawatra, Virendra Bhandari ,et al. Imatinib resistance in chronic myelogenous leukemia:an emerging challenge [J]. Int J Basic Clin Pharmacol, 2014,3 (5) : 908-911.
  • 3Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelo- genous leukemia treatment[J]. Ann Hemato1,2015,94 Suppl 2:123-131.
  • 4Li R, Chen WC, Pang XQ, et al. Influence of sCD40L on gastric cancer cell lines[J]. Mol Biol Rep, 201 I, 38 (8) : 5459-5464.
  • 5Kedar R, Sabag O, Licthenstein M,et al. Soluble CD40 ligand (sCD4OL) provides a new delivery system for targeted treatment :sCD40L-caspase 3 chimeric protein for treating B-cell malignancies[J].Cancer,2012,118(24):6089-6104.
  • 6李杰,陈琦,任明强.sCD40L对急性髓系白血病HL-60细胞生物学行为的影响及其机制[J].中华血液学杂志,2012,33(4):324-326. 被引量:8
  • 7Loskog AS ,Eliopoulos AG. The Janus faces of CD40 in cancer[J]. Semin lmmunol, 2009,21 (5) : 301-307.
  • 8Law CL, Grewal IS. Therapeutic interventions targeting CD40L ( CD 154) and CD40 :the opportunities and challenges[J]. Adv Exp Med Biol, 2009, 647 : 8-36.
  • 9刘珊,陈波,李燕,赵卫红,吴剑卿.sCD40L联合长春瑞滨对肺腺癌A549细胞的作用[J].中国肺癌杂志,2010,13(7):686-690. 被引量:4
  • 10王天立,黄建安,於葛华,毛一香,王光杰,张学光.可溶性CD40配体对肺癌细胞A549的生物学作用及其机制研究[J].癌症,2004,23(11):1278-1282. 被引量:9

二级参考文献63

共引文献52

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部